6362 completed, 2019 recruiting, 1751 unknown, 1677 terminated. 6168 Phase 2, 4549 Phase 1, 1352 Not applicable, 1296 Phase 3, 282 Early Phase 1.
Follow Immunoproliferative Disorders: new trials by email Literature Review of Immunoproliferative Disorders trials Research Report on Immunoproliferative Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FLASH Pilot Phase 1 Safety Study IntraOp Mobetron UHDR, Linac - Cutaneous Lymphoma | Not applicable | Not yet recruiting | Lesley A. Jarvis | 10 | 2029-10-31 | 2026-05-27 |
| A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia Blinatumomab, HyperCVAD - Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia | Phase 3 | Not yet recruiting | Amgen | 560 | 2028-06-30 | 2026-09-15 |
| Pyronaridine in Acute Myeloid Leukemia (AML) Pyronaridine Tetraphosphate - Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) | Phase 2 | Suspended | Armaceutica, Inc. | 200 | 2028-02-21 | 2026-10-19 |
| MM-CARE: Cardiovascular Risk Assessment in Adults With Multiple Myeloma Oncology-Embedded Cardiovascular Risk Assessment Pathway, Primary Care Provider-Directed Cardiovascular Risk Assessment Pathway - Multiple Myeloma, Heart Disease Risk Factors | Not applicable | Not yet recruiting | University of Vermont Medical Center | 33 | 2028-02-01 | 2026-08-25 |
| The Feasibility and Effects of Exercise on Patients Suffering From Multiple Myeloma Individual Exercise, Group Exercise - Multiple Myeloma | Not applicable | Suspended | Medical University of Vienna | 45 | 2027-09-01 | 2026-10-09 |
| Family-Focused Study to Support Medication for Opioid Use Disorder FamilyCHESS, Standard of Care - Opioid Use Disorder, Opioid Use Disorder, Moderate | Not applicable | Not yet recruiting | University of Wisconsin, Madison | 338 | 2027-08-31 | 2026-07-07 |
| Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 Trial Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | City of Hope Medical Center | 44 | 2027-08-04 | 2026-09-10 |
| Astragalus for Symptomatic Alleviation in High-grade Lymphoma Astragalus, Placebo - High-grade Lymphoma | Phase 3 | Not yet recruiting | Bnai Zion Medical Center | 60 | 2027-08-01 | 2026-09-30 |
| CAR-T Immunotherapy Targeting CD19- ALL 4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR - B-cell Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 100 | 2027-07-01 | 2026-08-26 |
| VR-PAT and fNIRS to Identify CNS Biomarkers of Pain VR-PAT - Acute Pain, Pediatric ALL | Not applicable | Not yet recruiting | Nationwide Children's Hospital | 4 | 2027-07-01 | 2026-09-09 |
| Engineered Dendritic Cell Vaccines for Multiple Myeloma DC vaccines - Multiple Myeloma or Plasmacytoma | Phase 1 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 10 | 2027-06-30 | 2026-08-27 |
| Universal 4SCAR7U Targeting CD7-positive Malignancies Universal CD7-specific CAR gene-engineered T cells - T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma | Phase 1 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-30 | 2026-08-26 |
| Multi-CAR-T Cells Targeting B Cell Lymphomas 4SCAR19 and 4SCAR20/22/70/PSMA/13/79b/GD2 - B Cell Lymphoma (BCL) | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 11 | 2027-06-01 | 2026-08-26 |
| ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma Allogeneic Hematopoietic Stem Cell Transplantation, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Cyclophosphamide - Multiple Myeloma, Recurrent Multiple Myeloma | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2027-06-01 | 2026-09-11 | |
| Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse Biospecimen Collection, Bone Marrow Biopsy, Carfilzomib - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 80 | 2027-05-22 | 2026-10-20 |
| Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell Therapy Prizloncabtagene Autoleucel - Large B Cell Lymphoma, LBCL | Phase 2 | Not yet recruiting | AbelZeta Inc. | 55 | 2027-05-01 | 2026-10-15 |
| Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration - Plasma Cell Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 74 | 2027-04-20 | 2026-10-07 |
| Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma Autologous BAFFR-targeting CAR T Cells, Biospecimen Collection, Bone Marrow Aspiration - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 16 | 2027-04-17 | 2026-08-11 |
| Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 162 | 2027-04-12 | 2026-10-16 |
| Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid Neoplasms: First-in-human Administration, COLIBRI. CAR-T anti-CD19 COL01 - Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies | Phase 1 | Not yet recruiting | GUSTAVO SALGUERO | 12 | 2027-04-01 | 2026-10-20 |
Showing 20 of 14207. Sign in to see all of them.
Multiple Myeloma (3659) · Lymphoma (3015) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2520) · Lymphoma, Non-Hodgkin (2287) · Leukemia, Lymphocytic, Chronic, B-Cell (2018) · Lymphoma, Follicular (1874) · Lymphoma, Large B-Cell, Diffuse (1824) · Leukemia (1379) · Hodgkin Disease (1301) · Lymphoma, Mantle-Cell (1209) · Recurrence (1153) · Leukemia, Myeloid, Acute (1032) · Burkitt Lymphoma (972) · Lymphoma, B-Cell, Marginal Zone (863) · Lymphoma, B-Cell (776)
Immune System Diseases (14138) · Hemic and Lymphatic Diseases (14058) · Neoplasms by Histologic Type (13935) · Lymphoproliferative Disorders (13893) · Neoplasms (13334) · Lymphatic Diseases (11116) · Hematologic Diseases (8231) · Lymphoma (5246) · Leukemia, Lymphoid (4249) · Paraproteinemias (4197) · Cardiovascular Diseases (4137) · Blood Protein Disorders (4124) · Vascular Diseases (4080) · Hemorrhagic Disorders (4050)
Cyclophosphamide (1572) · Rituximab (1438) · Dexamethasone (1270) · Lenalidomide (816) · Vincristine (696) · Bortezomib (667) · Doxorubicin (635) · Prednisone (581) · fludarabine (554) · Etoposide (546) · Cytarabine (516) · Melphalan (460) · Methotrexate (456) · fludarabine phosphate (435) · Filgrastim (418)
National Cancer Institute (NCI) (622) · M.D. Anderson Cancer Center (456) · Memorial Sloan Kettering Cancer Center (272) · Fred Hutchinson Cancer Center (177) · Mayo Clinic (161) · Celgene (159) · City of Hope Medical Center (158) · Novartis Pharmaceuticals (141) · Dana-Farber Cancer Institute (139) · Hoffmann-La Roche (138) · Institute of Hematology & Blood Diseases Hospital, China (127) · Children's Oncology Group (113) · St. Jude Children's Research Hospital (112) · Janssen Research & Development, LLC (109) · GlaxoSmithKline (100)
United States (7594) · China (2000) · France (1378) · Italy (1146) · Germany (984) · Spain (973) · Canada (944) · United Kingdom (940) · Australia (738) · South Korea (555) · Belgium (532) · Poland (473) · Netherlands (451) · Japan (422) · Israel (400)
PMID 34515338, PMID 41671463, PMID 35622074, PMID 40135712, PMID 32632956, PMID 32499241, PMID 34398557, PMID 31401903, PMID 40550489, PMID 33357481, PMID 38502198, PMID 39319495, PMID 39563886, PMID 26373676, PMID 31221778, PMID 37022569, PMID 37192741, PMID 37505794, PMID 38620092, PMID 22689675, PMID 23524640, PMID 27209293, PMID 27282998, PMID 31050355, PMID 33242441, PMID 39121442, PMID 40802906, PMID 23065508, PMID 23834234, PMID 29358183, PMID 30125215, PMID 31196847, PMID 32816215, PMID 33218965, PMID 34048072, PMID 35285981, PMID 35787017, PMID 40396505, PMID 40501401, PMID 41429239, PMID 18596230, PMID 19238148, PMID 26182309, PMID 28054442, PMID 28751558, PMID 28803351, PMID 30957581, PMID 31023700, PMID 32770353, PMID 33288485
2023 (163), P30CA033572 (108), P30CA015704 (88), 2017 (76), 2015 (75), P30CA015083 (75), 2016 (72), 2018 (68), 2014 (64), U10CA032102 (62), 2019 (56), U10CA180820 (55), 2025 (54), 2009 (51), P30CA016672 (44)